About
Copy Link
Titles
Hospital Resident
Biography
Internal Medicine Resident Physician at Yale New Haven Hospital, interested in classical hematology.
Former Postdoctoral Associate, Hematology, Yale Cancer Center (2021-2023)
Postdoctoral advisor: Alfred Ian Lee MD PhD
Research Interests: Hematology/Oncology, Decision Science, Cost effectiveness studies, Diversity Equity Inclusion in the Hematology Oncology Workforce, Medical education, Antiphospholipid syndrome, Rare diseases
Last Updated on November 20, 2024.
Departments & Organizations
Education & Training
- MBBS
- Aga Khan University (2021)
Research
Copy Link
Overview
Medical Research Interests
Hematology; Internal Medicine
ORCID
0000-0003-1172-2159
Research at a Glance
Yale Co-Authors
Frequent collaborators of Ayesha Butt's published research.
Publications Timeline
A big-picture view of Ayesha Butt's research output by year.
Research Interests
Research topics Ayesha Butt is interested in exploring.
Alfred Lee, MD, PhD
George Goshua, MD, MSc, FACP
Satoko Ito, MD, PhD
Alexander B. Pine, MD, PhD
Christopher Tormey, MD
Noffar Bar, MD
36Publications
105Citations
Publications
Featured Publications
Bias Against International Medical Graduates in the Hematology/Oncology Fellowship Recruitment Process: Findings From a Nationwide Survey of Fellowship Program Directors
Butt A, Mankbadi M, Erikson C, Marshall A, Masselink LE, Tong G, Hafler J, Podoltsev N, Lee AI. Bias Against International Medical Graduates in the Hematology/Oncology Fellowship Recruitment Process: Findings From a Nationwide Survey of Fellowship Program Directors. JCO Oncology Practice 2022, 18: 783-787. PMID: 36108253, DOI: 10.1200/op.22.00219.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and Concepts
2025
Analytical Review: Neutrophil Extracellular Traps and Antiphospholipid syndrome
Butt A, Sharda A, Lee A, Knight J. Analytical Review: Neutrophil Extracellular Traps and Antiphospholipid syndrome. Transfusion Medicine Reviews 2025, 150909. PMID: 40783311, DOI: 10.1016/j.tmrv.2025.150909.Peer-Reviewed Original ResearchCitationsAltmetricConceptsNeutrophil extracellular trapsAntiphospholipid syndromeAdenosine A2A receptorNegative regulatorP-selectin glycoprotein ligand-1Anti-NET antibodiesInduction of NETosisTranscription factor KLF2Regulation of NETosisAutoimmune prothrombotic disorderDecondensed chromatinDevelopment of thrombosisElevated NET levelsNeutrophil-mediated mechanismsGranule proteinsComplement system activationActivated Protein CObstetric complicationsAntiphospholipid antibodiesProthrombotic disordersNeutrophil-derived granule proteinsThrombotic eventsThrombotic riskClinical manifestationsAutoimmune disordersInternational Medical Graduates Representation at International Oncology Conference Meetings: An Analysis of ASCO Annual Meetings.
Roy A, Bakouny Z, Dizman N, Paul M, Ozay Z, Lal B, Nawfal R, Eid M, Chehade R, Machaalani M, Butt A, Aggarwal C, Bekaii-Saab T, Chavez-MacGregor M, Lopes G, Marshall A, Murphy M, Owonikoko T, Xie W, Lee A, Choueiri T. International Medical Graduates Representation at International Oncology Conference Meetings: An Analysis of ASCO Annual Meetings. JCO Oncology Practice 2025, op2500067. PMID: 40577682, DOI: 10.1200/op-25-00067.Peer-Reviewed Original ResearchAltmetricConceptsInternational medical graduatesAmerican medical graduatesASCO Annual MeetingFaculty rolesMedical graduatesInternational oncology meetingsMultivariate analysis assessed factorsOncology workforceOncology meetingsUnited StatesUnder-recognitionInvited facultyPracticing oncologistsFellowship traineesASCOConference meetingsOriginal researchPresentationMeetingAnnual MeetingPresent dataFacultyGraduatesAcademic rankWorkforce
2024
Deciding between Multiple Curative Options in Sickle Cell Disease: Cost-Effectiveness of Non-Myeloablative/Reduced Intensity Conditioning Haploidentical Allo-HSCT Vs Gene Therapy Vs Standard of Care in Adult Patients with Sickle Cell Disease
Chetlapalli K, Butt A, Ito S, Wang D, Calhoun C, Krishnamurti L, Pandya A, Goshua G. Deciding between Multiple Curative Options in Sickle Cell Disease: Cost-Effectiveness of Non-Myeloablative/Reduced Intensity Conditioning Haploidentical Allo-HSCT Vs Gene Therapy Vs Standard of Care in Adult Patients with Sickle Cell Disease. Blood 2024, 144: 601-601. DOI: 10.1182/blood-2024-203234.Peer-Reviewed Original ResearchConceptsChronic graft-versus-host diseaseSickle cell diseaseQuality-adjusted life yearsPost-transplant cyclophosphamideReduced intensity conditioningAllo-HSCTGene therapyCurative optionIncremental net monetary benefitProbabilistic sensitivity analysesMyeloablative conditioningHaploidentical donorsCell diseaseAdult patientsExpansion of donor poolUS health system perspectiveCenter for International Blood and Marrow Transplant ResearchGraft-versus-host diseaseEuropean Society for BloodSickle cell disease severityUS commercially insured patientsCost-effective therapeutic optionCost-effectiveness analysisAllo-HSCT outcomesDonor allo-HSCTGuide to Understanding and Supporting International Medical Graduates in Hematology/Oncology by the ASCO International Medical Graduates Community of Practice
Dizman N, Bakouny Z, Haykal T, Riano I, Desai A, Butt A, Basu A, Zhao D, Saad E, Saliby R, Gosain R, Gosain R, Ardeshir F, Deng L, Matt-Amaral L, Arnaoutakis K, Bekaii-Saab T, Manochakian R, Marshall A, Forde P, Murphy M, Subbiah V, Chavez-MacGregor M, Owonikoko T, Lopes G, Aggarwal C, Lee A, Choueiri T. Guide to Understanding and Supporting International Medical Graduates in Hematology/Oncology by the ASCO International Medical Graduates Community of Practice. JCO Oncology Practice 2024, 21: 292-299. PMID: 39374449, PMCID: PMC12455576, DOI: 10.1200/op-24-00565.Peer-Reviewed Original ResearchCitationsAltmetricConceptsInternational medical graduatesOncology workforceMedical graduatesContribution of international medical graduatesDiverse population of patientsOncology professionalsHematology/oncology fellowsUnited StatesFellowship trainingDiverse populationsMedical oncologyGreater awarenessPopulation of patientsWorkforceOncologyPracticing oncologistsSignificant hardshipASCOEarly career positionsUnique challengesCareer positionsHigh-qualityCommunities of practiceAwarenessCommunityPhenotypic and genotypic evaluation of bleeding diagnostic dilemmas: Two case studies
Gu S, Butt A, Schulz V, Rinder H, Lee A, Gallagher P, Hwa J, Bona R. Phenotypic and genotypic evaluation of bleeding diagnostic dilemmas: Two case studies. Blood Cells Molecules And Diseases 2024, 110: 102893. PMID: 39260211, DOI: 10.1016/j.bcmd.2024.102893.Peer-Reviewed Original ResearchCitationsConceptsInherited platelet disordersClinically significant bleedingCases of patientsHeterogeneous group of conditionsGroup of conditionsSignificant bleedingDiagnostic yieldDiagnostic dilemmaPlatelet disordersBleeding disordersEvaluating patientsPatient cohortMolecular pathogenesisMass cytometryHeterogeneous groupPatientsMultimodal approachBleedingImprove patient careDiagnosisDisordersPatient careGenetic sequencesLaboratory testing approachPotential utilityFactor VIII Levels and ISTH Disseminated Intravascular Coagulation Scores Do Not Distinguish Disseminated Intravascular Coagulation from the Coagulopathy of Liver Disease
Allen C, Heskel M, Butt A, Tormey C, Pine A, Lee A, Gautam S. Factor VIII Levels and ISTH Disseminated Intravascular Coagulation Scores Do Not Distinguish Disseminated Intravascular Coagulation from the Coagulopathy of Liver Disease. Acta Haematologica 2024, 148: 220-225. PMID: 39004080, PMCID: PMC12106121, DOI: 10.1159/000540239.Peer-Reviewed Original ResearchConceptsISTH DIC scoreFactor VIII levelsArea under the curveDIC scoreLiver diseaseFactor VIIIRetrospective chart review of patientsChart review of patientsCoagulopathy of liver diseaseReview of patientsRetrospective chart reviewCalculate area under the curveReceiver operating characteristic curveMultiple logistic regressionISTH scoreLaboratory parametersClinical challengeClinical utilityPatientsCharacteristic curveLab variablesLogistic regressionLiverDiseaseDiagnostic toolCost-effectiveness of bevacizumab therapy in the care of patients with hereditary hemorrhagic telangiectasia
Wang D, Ito S, Waldron C, Butt A, Zhang E, Krumholz H, Al-Samkari H, Goshua G. Cost-effectiveness of bevacizumab therapy in the care of patients with hereditary hemorrhagic telangiectasia. Blood Advances 2024, 8: 2835-2845. PMID: 38537061, PMCID: PMC11176968, DOI: 10.1182/bloodadvances.2024012589.Peer-Reviewed Original ResearchCitationsAltmetricConceptsIncremental net monetary benefitHereditary hemorrhagic telangiectasiaStandard-of-careBevacizumab therapyWillingness-to-payNet monetary benefitHemorrhagic telangiectasiaWillingness-to-pay thresholdsStandard-of-care strategiesCare of patientsCost-effectiveness analysisAnti-VEGF bevacizumabSystemic antiangiogenic therapyCurrent standard-of-careMonetary benefitsTime horizonFormulary placementHealthcare resource utilizationStandard of careLifetime time horizonPatient quality-of-lifeScenario analysisProbabilistic sensitivity analysesIV bevacizumabAnti-VEGFInternational medical graduates (IMG) representation at international oncology conference meetings.
Roy A, Bakouny Z, Dizman N, Ozay Z, Mohan Lal B, Nawfal R, Eid M, El Hajj Chehade R, Machaalani M, Butt A, Aggarwal C, Bekaii-Saab T, Chavez-MacGregor M, Lopes G, Marshall A, Murphy M, Owonikoko T, Lee A, CHOUEIRI T. International medical graduates (IMG) representation at international oncology conference meetings. Journal Of Clinical Oncology 2024, 42: 9000-9000. DOI: 10.1200/jco.2024.42.16_suppl.9000.Peer-Reviewed Original ResearchConceptsInternational medical graduatesAmerican medical graduatesASCO Annual MeetingMedical graduatesFaculty rolesMedical schoolsAmerican Society of Clinical Oncology (ASCOUS institutionsInternational oncology meetingsOncology workforceUnder-recognitionOncology meetingsSelection of presentationsAssess factorsMultivariate analysisPracticing oncologistsUS-basedASCOConference meetingsAcademic rankOriginal researchHighest proportionPodium presentationsAmerican SocietyUnited StatesCost-effectiveness of rapid vs in-house vs send-out ADAMTS13 testing for immune thrombotic thrombocytopenic purpura
Allen C, Ito S, Butt A, Purcell A, Richmond R, Tormey C, Krumholz H, Cuker A, Goshua G. Cost-effectiveness of rapid vs in-house vs send-out ADAMTS13 testing for immune thrombotic thrombocytopenic purpura. Blood Advances 2024, 8: 2279-2289. PMID: 38502197, PMCID: PMC11116991, DOI: 10.1182/bloodadvances.2024012608.Peer-Reviewed Original ResearchCitationsAltmetricConceptsImmune thrombotic thrombocytopenic purpuraPLASMIC scoreThrombotic thrombocytopenic purpuraThrombocytopenic purpuraADAMTS13 testingIncremental net monetary benefitPer-patient cost savingsTherapeutic plasma exchangeBase-case analysisMarkov cohort simulationProbabilistic sensitivity analysesAmount of QALYEmpirical therapyADAMTS13 assaysPlasma exchangeEmpirical treatmentCaplacizumabFRET-based assayPrimary outcomePatientsNet monetary benefitCohort simulationCost-effectiveness evaluationPurpuraTesting strategies
Academic Achievements & Community Involvement
Copy Link
Activities
activity JCO Oncology Practice
10/01/2022 - PresentPeer Review Groups and Grant Study SectionsReviewerDetailsPeer Reviewer
Honors
honor HTRS / Genentech "Best of ASH 2022"
12/11/2022Other AwardHemostasis and Thrombosis Research Society (HTRS)DetailsUnited Stateshonor Abstract selected for Highlights of ASH
12/11/2022Other AwardAmerican Society of HematologyDetailsUnited Stateshonor Abstract Achievement Award 2022
10/21/2022Other AwardAmerican Society of Hematology (ASH)DetailsUnited Stateshonor Young Investigator Travel Award
08/01/2022Other AwardThrombosis & Hemostasis Summit of North America (THSNA)DetailsUnited States
News
Copy Link
News
Get In Touch
Copy Link
Contacts
Email